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comparison with similar patients receiving NST or RIC regimens is
warranted.331
ASSOCIATION BETWEEN THE HEMATOPOIETIC CELL TRANSPLANTA-
TION-SPECIFIC COMORBIDITY INDEX (CIN) AND NON-RELAPSE MOR-
TALITY (NRM) AFTER REDUCED INTENSITY CONDITIONING (RIC)
ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) FOR ACUTE
MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION (CR1)
Mohty, M., Labopin, M., Basara, N., Cornelissen, J., Tabrizi, R.,
Malm, C., Perez-Simon, J.A., Nagler, A., Kroger, N., Rio, B.,
Martino, R., Eder, M., Bilger, K., Bunjes, D.W., Socie, G., Blaise, D.,
Polge, E., Rocha, V. On behalf of the Acute Leukemia Working Party
(ALWP) of EBMT
The adapted Charlson CIn (Sorror-CIn) was useful for predicting
NRM and survival in allo-SCT patients. However, the value of this
CI index is still under considerable debate, since the cohort used by
Sorror et al. (Blood 2005) included a heterogeneous group of pa-
tients. On the other hand, toxicities and NRM prediction is most
likely needed in elderly and medically infirm patients who are in-
creasingly offered RIC allo-SCT. Thus, the current study was de-
signed to test the performance of this CI and its association with
outcomes among a cohort of 345 patients (i) aged .50 y.; (ii) diag-
nosed with a single disease entity, AML in CR1, and (iii) who under-
went a RIC allo-SCT reported to the EBMT registry.
In this series, the median age was 58 y. (range, 50-76). A fludara-
bine-based RIC regimen was used in 64% of patients, while 31% re-
ceived low-dose TBI as part of their RIC, and 6% received other
non-specified RIC regimens. 76% of the patients received allo-
SCT from an HLA-matched sibling donor.
Based on score calculated with HR estimated on the population
studied, 161 patients (47%) had aCIn score of 0, 96 (29%) had a score
of 1, and 49 (14%) had a CI score of 2. 39 patients (11%) had CI
scores of 3 or more. In this cohort, 2 y. overall and LFS rates were
646 3% and 546 3% and the 2 y. relapse and -NRMcumulative in-
cidences (CI) were 326 2%, and 156 2% respectively. The 2 y.
NRM CI according to comorbidities score 0, 1, 2 and 3+ were
96 2%, 156 4%, 186 5% and 316 7%, respectively. In multivar-
iate models (adjusted for age, donor type, use of TBI or not, and cy-
togenetics risk group) comorbidities such as moderate active liver
disease, obesity, prior history of renal dysfunction, and prior history
of severe liver disease were associated with the highest HRs for 2 y.
NRM (varying from 2.11 to 2.76) and 2 y. CI of NRM varying from
22% to 44%, whereas previous solid tumor, diabetes, rheumatologic
abnormalities, moderate pulmonary diseases, cardiac abnormalities
(other than arrhythmia and valve disease) were associated with the
lowest HRs (varying from 0.2 to 1.0) with 2 y. CI of NRM varying
from 5 to 17%.
Results from this study performed in a single disease entity, sug-
gest that the hematopoietic cell transplantation-specific CIn is an in-
formative and useful tool for capturing pre-transplant comorbidities,
and for predicting NRM after RIC allo-SCT for AML in CR1 in
patients aged .50 y. Such index may be used for clinical trials and
patient counselling before RIC allo-SCT.332
A NOVEL REDUCED TOXICITY PREPARATIVE REGIMEN FOR HEMATO-
POIETIC CELL ALLOGRAFTING COMBINING PENTOSTATIN (NIPENT)
AND TARGETED DOSES OF INTRAVENOUS BUSULFAN (BUSULFEX)
WITH OR WITHOUT RITUXIMAB (PB6 R) USING CD4-GUIDED IMMUNE
SUPPRESSION: PRELIMINARY RESULTS OF AN ONGOING PROSPECTIVE
TRIAL
Kharfan-Dabaja, M.A.1, Perkins, J.1, Cortes, R.1, Brand, L.1,
Fernandez, H.F.1, Ochoa-Bayona, J.L.1, Field, T.1, Perez, L.1,
McIsaac, C.1, Maddox, B.1, Ayala, E.1, Komrokji, R.2, Pinilla-
Ibarz, J.2, Sotomayor, E.2, Tomblyn, M.1, Anasetti, C.1 1H. Lee Moffitt
Cancer Center, Tampa, FL; 2H. Lee Moffitt Cancer Center, Tampa, FL
This reduced toxicity regimen evaluates CD4-guided immune
suppression to facilitate early robust CD3 donor engraftment. Itconsists of a pre-conditioning treatment phase with Pentostatin
4 mg/m2 (days -28, -21, -14) if host CD4 counts are .100/uL; and
Rituximab 375 mg/m2 (days -21, -14, -7) in CD20+ lymphoid malig-
nancies. Conditioning phase consists of Pentostatin 4 mg/m2 (days
-4,-3) and two doses of I.V Busulfan (1st dose5 200 mg/m2 (day
-4) and 2nd dose (day-2)5 adjusted for cum. AUC5 16,000 micro-
mol*min/L 610%). Pts with CD20+ disease receive Rituximab
(375 mg/m2 on +1, +8). Primary study endpoint is$ 50% donor chi-
merism by day +28 (67) in CD3 + PB lymphocytes. At time of this
report 25 pts, M/F5 19/6, median age 56 (40-72) years, were evalu-
able. Diagnoses included 8 CLL (1 PR1, 1 CR2, 1 PR2, 5$ PR3), 4
mantle cell (1CR2, 2 PR2, 1 PR3), 4 follicular NHL (1CR2, 1 PR2,
1CR3, 1PR4), 2 Richter’s (1. PR2, 1CR3), 2 AML(1CR1, 1 PIF), 1
MDS (Persistent), 1 B-PLL (PR2), 1 T-cell NHL-NOS (PR2), 1 T-
PLL (PR1), and 1Waldestrom’s (PR1). Median (range) CD4 levels/
uL on days -28, -21, -14, -7, and 0 were 368 (27-842), 172 (33-571),
116 (41-277), 130 (43-344) and 34 (9-161), respectively. Median
(range) AUC for 1st, 2nd, and cum. Busulfan dose were 8,374
(6,058-11,124), 9,032 (5,432-13,215), and 17,567 (15,010-21,215),
respectively. All received G-CSF mobilized PBSC from 13 MRD,
7 MUD, 5 MMUD (B Ag5 2; C Ag5 1; DQ Ag5 2). Median
CD34+ dose infused was 9.01 (3.38-10.03) x106/kg cells. GVHD
prophylaxis was TAC-MTX in 21 (84%) and TAC-SIR in 4
(16%). No ATG was administered. Median (range) days to ANC
and PLAT engraftment were 17 (8-28) and 16 (10-33), respectively.
Twelve pts (48%) did not drop PLAT\20 K/uL. Median (range)
donor CD3, CD33 and unsorted BM chimerisms on day 28 (67
days) were 86% (59%-100%), 100% (95%-100%), 95% (90%-
100%), respectively (table 1). Non-relapse mortality at 100 days,
180 days, and at median F/U [269 (39-564) days] were 0%, 4%,
and 12%, respectively. One pt (MDS) died of progression. There
was no evidence of EBV reactivation or PTLD. aGVHD (max grade)
was: 05 4 (16%), I5 9 (36%), II5 9 (36%), III-IV5 3 (12%).
cGVHD by NIH consensus in 21 evaluable pts was: none5 5
(23.8%), mild5 5 (23.8%), mod5 8 (38.1%), and severe5 3
(14.3%). All but 5 pts received Rituximab making it not possible to
comment on its impact on GVHD at this time. PB6R is a safe reg-
imen that ensures early durable donor CD3 engraftment with mini-
mal NRM. Data will be updated at presentation.
Table 1.
Day 286 7 Day 906 7% Donor engraftment
by STR/PCR Median (range) Median (range)CD3 86% (59%-100%) 96% (77%-100%)
CD33 100% (95%-100%) 100% (100%-100%)
Unsorted BM 95% (90%-100%) 96% (78%-100%333
FREQUENCY OF ALLOGENEIC STEM CELL TRANSPLANT (SCT) IN PA-
TIENTS PRESENTING WITH NEWLY-DIAGNOSED AML OR AML AT TIME
OF FIRST SALVAGE THERAPY
Sandhu, R., Petersdorf, S., Sandmaier, B.M., O’Donnell, P., Becker, P.S.,
Deeg, H.J., Appelbaum, F.R., Estey, E.H. Fred Hutchinson Cancer Re-
search Center, Seattle, WA
Allogeneic SCT is widely considered the therapy most likely to
prolong survival in pts with AML in first complete remission
(CR1) or relapse (REL). Questions have arisen regarding the fre-
quency with which the procedure is undertaken in a defined popu-
lation of pts presenting with newly-diagnosed AML and
subsequently followed through REL and after, or in pts presenting
in REL. We first analyzed 26 consecutive pts age\70 who did not
have CBF AML, who were not NPM1+/FLT3-, and who achieved
CR1 with at least 4 months have elapsing from presentation date.
These patients would typically be considered candidates for SCT
in CR1. Eleven of the 26 (42%, 95% CI 23-63%) received SCT
at a median of 3.5 months (range 0.5-9.0) from CR date. Rates
